Abstract
In parallel to our better understanding of the role of the immune system in neurologic diseases, there has been an increased availability in therapeutic options for autoimmune neurologic diseases such as multiple sclerosis, myasthenia gravis, polyneuropathies, central nervous system vasculitides and neurosarcoidosis. In many cases, the purported benefits of this class of therapy are anecdotal and not the result of good controlled clinical trials. Nonetheless, their potential efficacy is better known than their adverse event profile. A rationale therapeutic decision by the clinician will depend on a comprehensive understanding of the ratio between efficacy and toxicity. In this review, we outline the most commonly used immune suppressive medications in neurologic disease: cytotoxic chemotherapy, nucleoside analogues, calcineurin inhibitors, monoclonal antibodies and miscellaneous immune suppressants. A discussion of their mechanisms of action and related toxicity is highlighted, with the goal that the reader will be able to recognize the most commonly associated toxicities and identify strategies to prevent and manage problems that are expected to arise with their use.
Keywords: Immunosuppressive therapy, toxicity, auto-immune neurologic disease, multiple sclerosis (MS), peptic disease, CNS vasculitides, Cyclophosphamide therapy, myasthenia gravis (MG), proximal myopathy
Current Neuropharmacology
Title: Toxicities of Immunosuppressive Treatment of Autoimmune Neurologic Diseases
Volume: 9 Issue: 3
Author(s): Enrico C. Lallana and Camilo E. Fadul
Affiliation:
Keywords: Immunosuppressive therapy, toxicity, auto-immune neurologic disease, multiple sclerosis (MS), peptic disease, CNS vasculitides, Cyclophosphamide therapy, myasthenia gravis (MG), proximal myopathy
Abstract: In parallel to our better understanding of the role of the immune system in neurologic diseases, there has been an increased availability in therapeutic options for autoimmune neurologic diseases such as multiple sclerosis, myasthenia gravis, polyneuropathies, central nervous system vasculitides and neurosarcoidosis. In many cases, the purported benefits of this class of therapy are anecdotal and not the result of good controlled clinical trials. Nonetheless, their potential efficacy is better known than their adverse event profile. A rationale therapeutic decision by the clinician will depend on a comprehensive understanding of the ratio between efficacy and toxicity. In this review, we outline the most commonly used immune suppressive medications in neurologic disease: cytotoxic chemotherapy, nucleoside analogues, calcineurin inhibitors, monoclonal antibodies and miscellaneous immune suppressants. A discussion of their mechanisms of action and related toxicity is highlighted, with the goal that the reader will be able to recognize the most commonly associated toxicities and identify strategies to prevent and manage problems that are expected to arise with their use.
Export Options
About this article
Cite this article as:
C. Lallana Enrico and E. Fadul Camilo, Toxicities of Immunosuppressive Treatment of Autoimmune Neurologic Diseases, Current Neuropharmacology 2011; 9 (3) . https://dx.doi.org/10.2174/157015911796557939
DOI https://dx.doi.org/10.2174/157015911796557939 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Virus-Associated Vasculitides
Current Immunology Reviews (Discontinued) Cardiovascular Complications of HIV Infection and Treatment
Cardiovascular & Hematological Agents in Medicinal Chemistry A<sub>3</sub> Adenosine Receptor: A Plausible Therapeutic Target for Cardio-Protection in Diabetes
Recent Patents on Cardiovascular Drug Discovery Lipophilic Guanylhydrazone Analogues as Promising Trypanocidal Agents: An Extended SAR Study
Current Pharmaceutical Design Pharmacological Therapy in Children with Atrial Fibrillation and Atrial Flutter
Current Pharmaceutical Design microRNA Regulation as a Therapeutic Strategy for Cardiovascular Disease
Current Drug Targets Distribution of Left Ventricular Thrombus among Patients with Significantly Impaired Systolic Function
New Emirates Medical Journal Geriatric Psychopharmacology in Acute Settings
Current Psychopharmacology Expression of microRNAs (133b and 138) and Correlation with Echocardiographic Parameters in Patients with Alcoholic Cardiomyopathy
MicroRNA Redox Control of Cardiovascular Homeostasis by Angiotensin II
Current Pharmaceutical Design Targeting SUMOylation Cascade for Diabetes Management
Current Drug Targets Phosphoinositide-3 Kinase Signaling in Cardiac Hypertrophy and Heart Failure
Current Pharmaceutical Design The Role of Apelins in the Physiology of the Heart
Protein & Peptide Letters Periostin as a Heterofunctional Regulator of Cardiac Development and Disease
Current Genomics Reversal of Cardiac Iron Loading and Dysfunction in Thalassemic Mice by Curcuminoids
Medicinal Chemistry Accumulation of Intraneuronal Amyloid-β is Common in Normal Brain
Current Alzheimer Research Drugs as Possible Triggers of Takotsubo Cardiomyopathy- Update 2022: Systematic Review
Current Vascular Pharmacology Cardiac Stem Cell-Based Myocardial Regeneration: Towards a Translational Approach
Cardiovascular & Hematological Agents in Medicinal Chemistry The Prostaglandin Agonist Beraprost Aggravates Doxorubicin-mediated Apoptosis by Increasing iNOS Expression in Cardiomyocytes
Current Vascular Pharmacology Stem Cell Based Preclinical Drug Development and Toxicity Prediction
Current Pharmaceutical Design